Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 61 to 70 of 797

TitleReference numberPublishedLast updated
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Cabozantinib with nivolumab for untreated advanced renal cell carcinomaTA964
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA963
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapyTA962
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal)TA965
Ritlecitinib for treating severe alopecia areata in people 12 years and overTA958
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosisTA959
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960

Results per page

  1. 10
  2. 25
  3. 50
  4. All